Media Articles Related to Uroxatral (Alfuzosin)
Benign Prostatic Hyperplasia
Source: MedicineNet Blood In Urine Specialty [2015.05.19]
Title: Benign Prostatic Hyperplasia
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 5/19/2015 12:00:00 AM
Benign Prostatic Hyperplasia (Enlarged Prostate) Quiz
Source: MedicineNet Prostatitis Specialty [2012.02.29]
Title: Benign Prostatic Hyperplasia (Enlarged Prostate) Quiz
Category: MedicineNet Quiz
Created: 2/7/2012 3:29:00 PM
Last Editorial Review: 2/29/2012 6:25:09 PM
Published Studies Related to Uroxatral (Alfuzosin)
Medical expulsive therapy using alfuzosin for patient presenting with ureteral stone less than 10mm: a prospective randomized controlled trial. [2011.07]
OBJECTIVES: To assess the spontaneous passage rate for patients being treated with alfuzosin 10mg daily after presenting with an acute ureteral stone compared with a control group, and to assess the respective pain control status... CONCLUSIONS: MET using alfuzosin SR 10mg daily is effective to enhance the ureteral stone spontaneous passage rate, particularly for upper ureteral stones. Fewer analgesic drugs are consumed and more patients can avoid ureteroscopic lithotripsy and/or extracorporeal shock wave lithotripsy. (c) 2011 The Japanese Urological Association.
The effects of tolterodine extended release and alfuzosin for the treatment of double-j stent-related symptoms. [2009.11]
AIM: To evaluate the effects of tolterodine extended release (ER) and alfuzosin for the treatment of Double-J stent-related lower urinary tract symptoms... CONCLUSIONS: Tolterodine ER and alfuzosin improve stent-related urinary symptoms and body pain.
Prospective randomized trial comparing efficacy of alfuzosin and tamsulosin in management of lower ureteral stones. [2009.04]
OBJECTIVES: To study the efficacy of alfuzosin compared with tamsulosin in the management of lower ureteral stones... CONCLUSIONS: Medical treatment of lower ureteral calculi with tamsulosin and alfuzosin resulted in a significantly increased stone expulsion rate, decreased expulsion time, and a reduced need for analgesic therapy.
Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. [2009.02]
INTRODUCTION: Alpha1-blockers (AB) are the first-line monotherapy for lower urinary tract symptoms (LUTS). Phosphodiesterase type 5 (PDE5) inhibitors are the first-line treatment for erectile dysfunction (ED). Numerous studies have supposed a significant association between ED and LUTS, but a causal relationship cannot be established. AIM: The aim was to evaluate the efficacy of a combined therapy with an AB (alfuzosin) and PDE5 inhibitors (tadalafil) in patients with LUTS and ED... CONCLUSIONS: Combined therapy improved ED and LUTS as demonstrated by the significant improvement in uroflowmetry measures and in IPSS and IIEF-EF scores. A significant improvement was also observed in quality of life assessments. The beneficial effects of tadalafil on LUTS similar to the benefits of alfuzosin on ED, although present, were smaller.
Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study. [2009.01]
PURPOSE: We assessed the impact of alfuzosin on ureteral stent discomfort... CONCLUSIONS: Alfuzosin improves the patient discomfort associated with ureteral stents by decreasing urinary symptoms and kidney pain but it does not affect the amount of narcotics that patients use while the stent is in place.
Clinical Trials Related to Uroxatral (Alfuzosin)
The Long Term Effects of Alfuzosin(Xatral XL) in LUTS/BPH Patients: Evaluation of Voiding and Storage Function [Active, not recruiting]
Benign prostatic hyperplasia (BPH) is a common condition among older men. The efficacy of
α1-blockers for treating BPH has been well documented and they are recommended for the
treatment of BPH by clinical guidelines.
It is not well known if a stratification based on the grade of BOO and bladder contractility
has any predictive value for patients who are treated with an α1-selective blocking agent. In
our study, we investigated possible differences in treatment outcome between patients with
and without BOO, and with or without proper contractility who are treated with alfuzosin. So
we will compare the quantified improvements 12 months after alfuzosin medication in LUTS/BPH
patients by the grade of BOO and/or bladder contractility.
Alfuzosin for Voiding Dysfunction in Multiple Sclerosis (MS) [Recruiting]
Multiple Sclerosis is often associated with severe functional deficits resulting in a range
of progressive impairments. Approximately 80% of patients have bladder symptoms at the time
of diagnosis and up to 97% will have bladder symptoms during the course of the disease. To
date, the vast majority of treatment has been centered on the use of medications to control
"bladder spasms" and the use of catheters to help patients empty the bladder. There have
been very few studies looking at medications like Alfuzosin that may help in controlling
bladder symptoms in Multiple Sclerosis. Alfuzosin has been shown to significantly improve
voiding symptoms and bladder emptying in patients with prostatic enlargement. There have
been no controlled studies yet to determine whether this treatment helps patients with
Multiple Sclerosis. The purpose of this study is to determine if Alfuzosin improves bladder
symptoms and quality of life in patients with Multiple Sclerosis.
Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL®) in Patients With Benign Prostate Hypertrophy [Completed]
To collect under daily practice conditions, clinical data on the changes of sexual function
when a new formulation of alfuzosin(Xatral XL® )is administered once daily in patients with
lower urinary tract symptoms(LUTS) suggestive of prostatic hypertrophy
Alfuzosin XL Lower Urinary Tract Symptoms Efficacy and Sexuality Study [Completed]
To assess, under daily practice conditions, the safety profile and the efficacy of a new
formulation of alfuzosin administered once daily (Xatral XL) in patients with lower urinary
tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).
Once Daily Given Alfuzosin in the Treatment of BPH [Completed]
Collection of the data on the safety and efficacy of the once daily administration of the
alfuzosin preparation /Alfetim Uno® l0 mg/ at patients with lower urinary tract
symptoms/complaints rendering possible the presence of benign prostatic hyperplasia, in the
course of everyday practice
Reports of Suspected Uroxatral (Alfuzosin) Side Effects
Muscular Weakness (3),
Gait Disturbance (3),
Urinary Incontinence (2),
Erectile Dysfunction (2),
Throat Tightness (2),
Cough (2), more >>